First human doses given for rare brain disease treatment
NCT ID NCT06517914
Summary
This is the first study to test a new oral drug, called YH35995, in people. The goal is to check its basic safety and how the body processes it in healthy male volunteers. This is an early, necessary step to see if the drug could later help treat the brain-related symptoms of a rare condition called Gaucher disease type 3.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam, Bundang-gu, 13496, South Korea
Contact
Conditions
Explore the condition pages connected to this study.